Market Cap 50.04B
Revenue (ttm) 5.44B
Net Income (ttm) 4.17B
EPS (ttm) N/A
PE Ratio 33.67
Forward PE 33.42
Profit Margin 76.75%
Debt to Equity Ratio 0.06
Volume 704,700
Avg Vol 4,189,434
Day's Range N/A - N/A
Shares Out 580.30M
Stochastic %K 87%
Beta 0.97
Analysts Strong Sell
Price Target $95.68

Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. I...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 250 2500
Address:
One Edwards Way, Irvine, United States
AnachronismA
AnachronismA Dec. 25 at 4:48 AM
$EW The next inflection point emerges from the pace at which operating leverage materializes relative to expectations, with outcomes shaped by timing and discipline. Missteps risk prolonged valuation stagnation.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 23 at 5:36 PM
0 · Reply
Thelonius_Stonk
Thelonius_Stonk Dec. 23 at 5:06 PM
$EW 👀
0 · Reply
GettnFibbywIT
GettnFibbywIT Dec. 23 at 3:39 PM
$EW $XLV $IHI Just sayin' - Price still trying to get above........
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 5:45 PM
Winning streaks into 2026? Big MedTech says yes. 🏥📈 Four large-cap MedTech leaders — $MDT, $ISRG, $CAH, and $EW — appear well-positioned to keep momentum going into 2026, backed by resilient procedure demand and ongoing innovation driving their businesses. Want the full breakdown on what’s powering these names? See the full MedTech outlook here 👉 https://www.zacks.com/stock/news/2807489/4-large-cap-medtech-stocks-to-keep-winning-streaks-alive-in-2026?cid=sm-stocktwits-2-2807489-teaser-25846&ADID=SYND_STOCKTWITS_TWEET_2_2807489_TEASER_25846
0 · Reply
1iquid
1iquid Dec. 20 at 12:17 PM
OptionWizards Tip (education only): Always define max loss before entering an options trade. $RKT $EW $VEEV Not financial advice.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 3:35 PM
$EW Analysis: The last close is $84.8, with an RSI of 41.99 indicating a potential oversold condition. The price is slightly above the 30-day moving average (MA30) of $84.83, suggesting a neutral short-term trend. However, the 50-day moving average (MA50) at $81.92 indicates a bullish trend in the medium term. The recent 60-day high of $87.89 and low of $72.3 provides a range that suggests potential upside. Trade Plan: - Suggested Entry: $84.80 - Stop Loss: $82.00 (below MA50 for protection) - Take Profit Targets: - Target 1: $86.00 (1.41% gain) - Target 2: $87.00 (2.65% gain) - Target 3: $99.00 (16.78% gain) With a favorable risk-reward ratio, this trade can yield over 17% ROI at Target 3. The current market context and technical indicators support a bullish bias. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 18 at 1:40 PM
JP Morgan updates rating for Edwards Lifesciences ( $EW ) to Overweight, target set at 90 → 100.
0 · Reply
JarvisFlow
JarvisFlow Dec. 17 at 7:59 PM
Canaccord Genuity has adjusted their stance on Edwards Lifesciences ( $EW ), setting the rating to Hold with a target price of 89 → 87.
0 · Reply
JackDarwin
JackDarwin Dec. 17 at 1:14 PM
$EW Bullish Engulfing Candlestick Pattern formed. Wait for the confirmation from the next day's candle.
0 · Reply
Latest News on EW
Top small-cap plays for 2026

Nov 25, 2025, 1:24 PM EST - 4 weeks ago

Top small-cap plays for 2026

A COHR DG TXT VLO


Edwards Lifesciences CFO Scott Ullem to step down by mid-2026

Oct 30, 2025, 4:38 PM EDT - 7 weeks ago

Edwards Lifesciences CFO Scott Ullem to step down by mid-2026


Edwards Lifesciences Announces CFO Transition Plan

Oct 30, 2025, 4:15 PM EDT - 7 weeks ago

Edwards Lifesciences Announces CFO Transition Plan


Edwards Lifesciences Reports Third Quarter Results

Oct 30, 2025, 4:13 PM EDT - 7 weeks ago

Edwards Lifesciences Reports Third Quarter Results


Edwards Lifesciences: Inflection Incoming, But When?

Oct 14, 2025, 2:36 PM EDT - 2 months ago

Edwards Lifesciences: Inflection Incoming, But When?


Edwards Lifesciences Reports Second Quarter Results

Jul 24, 2025, 4:15 PM EDT - 5 months ago

Edwards Lifesciences Reports Second Quarter Results


Edwards Lifesciences: With A Heart Beating Strong And Steady

Jun 4, 2025, 2:11 PM EDT - 7 months ago

Edwards Lifesciences: With A Heart Beating Strong And Steady


Trade Tracker: Bill Baruch buys Edwards Lifesciences

May 19, 2025, 2:13 PM EDT - 7 months ago

Trade Tracker: Bill Baruch buys Edwards Lifesciences


Edwards Lifesciences Reports First Quarter Results

Apr 23, 2025, 4:15 PM EDT - 8 months ago

Edwards Lifesciences Reports First Quarter Results


AnachronismA
AnachronismA Dec. 25 at 4:48 AM
$EW The next inflection point emerges from the pace at which operating leverage materializes relative to expectations, with outcomes shaped by timing and discipline. Missteps risk prolonged valuation stagnation.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 23 at 5:36 PM
0 · Reply
Thelonius_Stonk
Thelonius_Stonk Dec. 23 at 5:06 PM
$EW 👀
0 · Reply
GettnFibbywIT
GettnFibbywIT Dec. 23 at 3:39 PM
$EW $XLV $IHI Just sayin' - Price still trying to get above........
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 5:45 PM
Winning streaks into 2026? Big MedTech says yes. 🏥📈 Four large-cap MedTech leaders — $MDT, $ISRG, $CAH, and $EW — appear well-positioned to keep momentum going into 2026, backed by resilient procedure demand and ongoing innovation driving their businesses. Want the full breakdown on what’s powering these names? See the full MedTech outlook here 👉 https://www.zacks.com/stock/news/2807489/4-large-cap-medtech-stocks-to-keep-winning-streaks-alive-in-2026?cid=sm-stocktwits-2-2807489-teaser-25846&ADID=SYND_STOCKTWITS_TWEET_2_2807489_TEASER_25846
0 · Reply
1iquid
1iquid Dec. 20 at 12:17 PM
OptionWizards Tip (education only): Always define max loss before entering an options trade. $RKT $EW $VEEV Not financial advice.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 3:35 PM
$EW Analysis: The last close is $84.8, with an RSI of 41.99 indicating a potential oversold condition. The price is slightly above the 30-day moving average (MA30) of $84.83, suggesting a neutral short-term trend. However, the 50-day moving average (MA50) at $81.92 indicates a bullish trend in the medium term. The recent 60-day high of $87.89 and low of $72.3 provides a range that suggests potential upside. Trade Plan: - Suggested Entry: $84.80 - Stop Loss: $82.00 (below MA50 for protection) - Take Profit Targets: - Target 1: $86.00 (1.41% gain) - Target 2: $87.00 (2.65% gain) - Target 3: $99.00 (16.78% gain) With a favorable risk-reward ratio, this trade can yield over 17% ROI at Target 3. The current market context and technical indicators support a bullish bias. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 18 at 1:40 PM
JP Morgan updates rating for Edwards Lifesciences ( $EW ) to Overweight, target set at 90 → 100.
0 · Reply
JarvisFlow
JarvisFlow Dec. 17 at 7:59 PM
Canaccord Genuity has adjusted their stance on Edwards Lifesciences ( $EW ), setting the rating to Hold with a target price of 89 → 87.
0 · Reply
JackDarwin
JackDarwin Dec. 17 at 1:14 PM
$EW Bullish Engulfing Candlestick Pattern formed. Wait for the confirmation from the next day's candle.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:22 AM
$EW Actionable Trade Alert: Market Context: $EW is currently trading at $85.45, showing a neutral RSI of 52.65, indicating potential for upward movement. The recent price is above the 30-day moving average (MA30) of $84.75, suggesting bullish momentum. The 60-day high of $87.89 presents a resistance level, while the low of $72.3 indicates a strong support base. Directional Bias: The price action above MA30 and the neutral RSI suggests a potential bullish trend. The proximity to the 60D high provides an opportunity for upward movement. Trade Plan: - Suggested Entry: $85.50 - Stop Loss: $83.50 (risking $2.00) - Take Profit Targets: 1. TP1: $87.00 (17.6% ROI) 2. TP2: $88.50 (20.3% ROI) 3. TP3: $90.00 (24.3% ROI) With the current metrics, this trade plan offers a favorable risk-reward ratio while targeting significant returns. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 16 at 11:31 AM
Baird has updated their rating for Edwards Lifesciences ( $EW ) to Neutral with a price target of 87.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 5:56 AM
$EW Actionable Trade Alert: Market Context: $EW is currently trading at $83.08, showing a neutral RSI of 41.87, indicating potential for upward movement. The stock is below the 30-day moving average (MA30) of 84.64 but above the 50-day moving average (MA50) of 81.42, suggesting a possible bullish reversal. Directional Bias: The recent price action is near the 60-day low of 72.3, providing a favorable risk-reward setup. The ATR of 1.58 indicates moderate volatility, allowing for reasonable price movement. Trade Plan: - Suggested Entry: $83.10 - Stop Loss: $80.50 (3% risk) - Take Profit Targets: 1. $85.00 (Target 1: 2.3% ROI) 2. $86.50 (Target 2: 4.9% ROI) 3. $97.00 (Target 3: 16.8% ROI) With a focus on the potential upside and favorable risk-reward, this trade plan aims for a significant return while managing risk effectively. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 10:49 PM
$EW Actionable Trade Alert: Market Context: Currently trading at $83.9, $EW is positioned within a range defined by a 60D high of $87.89 and a low of $72.3. The RSI at 49.22 indicates a neutral momentum, suggesting potential for upward movement. Directional Bias: The price is above the MA50 of $81.28 but below the MA30 of $84.65, indicating a potential bullish reversal if it breaks above the MA30. The ATR of 1.59 suggests moderate volatility, allowing for reasonable price movement. Trade Plan: - Suggested Entry: $84.00 (break above MA30) - Stop Loss: $81.00 (below MA50) - Take Profit Targets: 1. $86.00 (1st target, 2.38% ROI) 2. $88.00 (2nd target, 4.76% ROI) 3. $98.00 (3rd target, 17.00% ROI) This plan provides a clear pathway to capitalize on potential upward momentum while managing risk effectively. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 8:59 PM
Citigroup updates rating for Edwards Lifesciences ( $EW ) to Buy, target set at 96 → 101.
0 · Reply
ZacksResearch
ZacksResearch Dec. 11 at 1:29 PM
$EW's TAVR business is on fire! 🚀 With a 10.6% YoY growth in Q3 2025, FDA approval for asymptomatic AS patients, and broad-based adoption of the SAPIEN platform in Europe, Edwards is positioned for a strong run. Find out what could drive Edwards higher 👉 https://www.zacks.com/stock/news/2802754/should-you-continue-to-hold-ew-stock-in-your-portfolio?cid=sm-stocktwits-2-2802754-body-24362&ADID=SYND_STOCKTWITS_TWEET_2_2802754_BODY_24362
0 · Reply
ZacksResearch
ZacksResearch Dec. 11 at 12:10 PM
Is $EW still worth a spot in your portfolio? 🤔 The headline is raising the exact question long-term holders should be asking — whether EW remains a hold or if the risk/reward has shifted. That alone tells me this is a moment to reassess the setup. Dig into the full hold-or-fold breakdown here 👉 https://www.zacks.com/stock/news/2802754/should-you-continue-to-hold-ew-stock-in-your-portfolio?cid=sm-stocktwits-2-2802754-teaser-24336&ADID=SYND_STOCKTWITS_TWEET_2_2802754_TEASER_24336
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 2:52 AM
$EW Actionable Trade Alert: Market Context: The stock closed at $83.26, showing a neutral RSI of 47.48, indicating no immediate overbought or oversold conditions. The price is currently between the 60D high of $87.89 and the low of $72.3, suggesting potential for upward movement. Directional Bias: The price is above the MA50 of $81.01 but below the MA30 of $84.55, indicating a potential bullish reversal. The proximity to the 60D high further supports a bullish outlook. Trade Plan: - Suggested Entry: $83.50 - Stop Loss: $81.00 (2.8% risk) - Take Profit Targets: 1. $86.00 (3% gain) 2. $88.00 (5.9% gain) 3. $97.00 (16.5% gain) With a target of $97.00, this trade offers a potential ROI of over 17%. Monitor closely for market conditions and adjust stops as needed. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 10:40 PM
$EW: Current market context shows a stable price action with the last close at $84.49, near the 30-day moving average (MA30) of $84.47, indicating potential support. The RSI at 49.16 suggests the stock is neither overbought nor oversold, providing a neutral bias. The price is also above the 50-day moving average (MA50) of $80.89, which is bullish. Directional bias leans slightly bullish, considering the proximity to the MA30 and the recent high of $87.89. The 60-day low of $72.3 offers a solid risk-reward ratio. Suggested entry: $84.50. Stop loss: $82.50 (risking $2.00). Take Profit Targets: 1) $86.00 (2% gain) 2) $88.00 (4% gain) 3) $99.00 (17% gain) This trade plan allows for a strong upside potential while maintaining a manageable risk. Monitor the ATR of 1.79 for volatility adjustments. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
GettnFibbywIT
GettnFibbywIT Dec. 8 at 3:52 PM
$EW $XLV $IHI Would you look at that...A big area for EW bulls to overcome/close above:
0 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 3:38 PM
Barclays updates rating for Edwards Lifesciences ( $EW ) to Overweight, target set at 99 → 103.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:41 AM
$EW Actionable Trade Alert: Market Context: The last close at $85.78 indicates a stable position within the recent trading range. The RSI at 48.87 suggests neutral momentum, while the MA30 and MA50 are both trending upwards, indicating potential bullish sentiment. Directional Bias: Given the current price is above the MA30 (83.87) and MA50 (80.51), there is a bullish bias. The 60D high of $87.4 provides a near-term resistance level, while the 60D low of $72.3 offers support. Trade Plan: - Suggested Entry: $86.00 (slightly above last close to confirm momentum) - Stop Loss: $83.00 (to limit risk) - Take Profit Targets: 1. $88.00 (2.33% gain) 2. $90.00 (4.67% gain) 3. $100.00 (16.54% gain) This plan provides a potential ROI of over 17% on the third target while maintaining a favorable risk-reward ratio. Monitor the trade closely for market fluctuations. https://privateprofiteers.com
0 · Reply